CONTRACEPTION IN PATIENTS WITH OBESITY
Abstract
The article presents modern possibilities of the use of hormonal contraceptives in the form of combined estrogen-gestagenic agents, of gestagenic contraceptives, intrauterine equipment, implants and adhesive bandages. Discussedmainissuesof efficiency, safety and acceptability of the use of these funds in the high-risk group for the development of complications.
About the Authors
I. O. Makarov
GBOU VPO “First Moscow state medical university named after I.M. Sechenov” of Ministry of Healthcare of Russia
Russian Federation
Russian Federation
E. I. Borovkova
GBOU VPO “First Moscow state medical university named after I.M. Sechenov” of Ministry of Healthcare of Russia
Russian Federation
Russian Federation
References
1. Abdollahi M., Cushman M., Rosendaal F.R. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb. Haemost. 2003; 89: 493.
2. Brunner Huber L.R., Toth J.L. Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth. Am. J. Epidemiol. 2007; 166: 1306.
3. Burkman R.T., Fisher A.C., Wan G.J. et al. Association between efficacy and body weight or body mass index for two low-dose oral contraceptives. Contraception 2009; 79: 424.
4. Coney P., Washenik K., Langley R.G. et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception 2001; 63: 297.
5. Centers for Disease Control and Prevention (CDC). U S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm. Rep. 2010; 59: 1.
6. Edelman A., Jensen J.T., Bulechowsky M., Cameron J. Combined oral contraceptives and body weight: do oral contraceptives cause weight gain? A primate model. Hum. Reprod. 2011; 26: 330.
7. Edelman A.B., Cherala G., Stanczyk F.Z. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. Contraception 2010; 82: 314.
8. Edelman A.B., Carlson N.E., Cherala G. et al.Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitaryovarian activity. Contraception 2009; 80: 119.
9. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 1582.
10. Fishman J., Boyar R.M., Hellman L. Influence of body weight on estradiol metabolism in young women. J. Clin. Endocrinol. Metab. 1975; 41: 989.
11. Funk S., Miller M.M., Mishell D.R. Jr. et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005; 71: 319.
12. Holt V.L., Scholes D., Wicklund K.G. et al. Body mass index, weight, and oral contraceptive failure risk. Obstet. Gynecol. 2005; 105: 46.
13. Holt V.L., Cushing-Haugen K.L., Daling J.R. Body weight and risk of oral contraceptive failure. Obstet. Gynecol. 2002; 99: 820.
14. Grimes D.A., Shields W.C. Family planning for obese women: challenges and opportunities. Contraception 2005; 72: 1.
15. Gu S., Sivin I., Du M. et al. Effectiveness of Norplant implants through seven years: a largescale study in China. Contraception 1995; 52: 99.
16. Gu S.J., Du M.K., Zhang L.D. et al. A 5-year evaluation of NORPLANT contraceptive implants in China. Obstet. Gynecol. 1994; 83: 673.
17. Grubb G.S., Moore D., Anderson N.G. Preintroductory clinical trials of Norplant implants: a comparison of seventeen countries' experience. Contraception. 1995; 52: 287.
18. Goldzieher J.W., Moses L.E., Averkin E. et al. A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Fertil. Steril. 1971; 22: 609.
19. Gallo M.F., Lopez L.M., Grimes D.A. et al. Combination contraceptives: effects on weight. Cochrane Database Syst. Rev. 2006;CD003987.
20. Kaunitz A.M. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians. Int. J. Fertil. Womens. Med. 1998; 43: 73.
21. Medical Eligibility Criteria for Contraceptive Use (UK MEC 2005/2006), Faculty of Family Planning and Reproductive Health Care, London. 2006.
22. Mornar S., Chan L.N., Mistretta S. et al. Pharmacokinetics of the etonogestrel contraceptive implant in obese women. Am. J. Obstet. Gynecol. 2012; 207: 110.e1.
23. Nightingale A.L., Lawrenson R.A., Simpson E.L. et al. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur. J. Contracept. Reprod. Health. Care 2000; 5: 265.
24. Ogden C.L., Carroll M.D., Curtin L.R. et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549.
25. Pelkman C.L., Chow M., Heinbach R.A., Rolls B.J. Short-term effects of a progestational contraceptive drug on food intake, resting energy expenditure, and body weight in young women. Am. J. Clin. Nutr. 2001; 73: 19.
26. Riphagen F.E., Fortney J.A., Koelb S. Contraception in women over forty. J. Biosoc. Sci 1988; 20: 127.
27. Speerhas R. Drug metabolism in malnutrition and obesity: clinical concerns. Cleve Clin. J. Med. 1995; 62: 73.
28. Stadel B.V., Sternthal P.M., Schlesselman J.J. et al. Variation of ethinylestradiol blood levels among healthy women using oral contraceptives. Fertil. Steril. 1980; 33: 257.
29. Samama M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch. Intern. Med. 2000; 160: 3415.
30. Trussell J., Schwarz E.B., Guthrie K. Obesity and oral contraceptive pill failure. Contraception 2009; 79: 334. 31. Trussell J., Guthrie K.A., Schwarz E.B. Much ado about little: obesity, combined hormonal contraceptive use and venous thrombosis. Contraception. 2008; 77: 143.
31. Vessey M. Oral contraceptive failures and body weight: findings in a large cohort study. J. Fam. Plann. Reprod. Health Care 2001; 27: 90.
32. Westhoff C.L., Torgal A.H., Mayeda E.R. et al. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception 2010; 81: 474.
33. U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition. http://www.cdc.gov/mmwr/pdf/rr/rr59e0528.pdf (Accessed on August 03, 2011).
34. Xu H., Wade J.A., Peipert J.F. et al. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet. Gynecol. 2012; 120: 21.
35. Zieman M., Guillebaud J., Weisberg E. et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil. Steril. 2002; 77: 13.
Review
For citations:
Makarov I.O., Borovkova E.I. CONTRACEPTION IN PATIENTS WITH OBESITY. Obstetrics, Gynecology and Reproduction. 2013;7(1):36-40. (In Russ.)
Views:
518
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
